Unexpectedly, the same analysis revealed a clear trend towards worsening inflammation in the IFX-treated WT groups and, again, no or limited response to the drug in the transporter-deficient strain ( Figure 1 , panels C and D).
← all excerpts
Solute Transporter OCTN1/Slc22a4 Affects Disease Severity and Response to Infliximab in Experimental Colitis: Role of Gut Microbiota and Immune Modulation.
1
—
—